150407-69-5

Usage

Uses

Used in Organic Synthesis:
(S)-N-4-BOC-N-1-CBZ-2-PIPERAZINE CARBOXYLIC ACID is used as a synthetic intermediate for the preparation of various organic compounds. Its protective groups and piperazine ring structure make it a versatile building block in the synthesis of complex molecules, particularly in the pharmaceutical and chemical industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (S)-N-4-BOC-N-1-CBZ-2-PIPERAZINE CARBOXYLIC ACID is used as a key intermediate in the synthesis of drug candidates. The protective groups facilitate the introduction of additional functional groups and the piperazine ring can be a part of the final drug molecule, contributing to its biological activity.
Used in Chemical Research:
(S)-N-4-BOC-N-1-CBZ-2-PIPERAZINE CARBOXYLIC ACID is employed as a research compound in academic and industrial laboratories. It serves as a model system for studying the reactivity and properties of compounds with similar structures, as well as for exploring new synthetic methodologies and reaction mechanisms.

InChI:InChI=1/C18H24N2O6/c1-18(2,3)26-16(23)19-9-10-20(14(11-19)15(21)22)17(24)25-12-13-7-5-4-6-8-13/h4-8,14H,9-12H2,1-3H3,(H,21,22)/t14-/m0/s1

Upstream product

• 501-53-1 benzyl chloroformate 
• 128019-59-0 piperazine-1,3-dicarboxylic acid 1-tert-butyl ester 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 848482-93-9 (S)-4-(tert-butoxycarbonyl)piperazine-2-carboxylic acid 

Downstream Products

• 150323-34-5 N-tert-butyl-4-<(1,1-dimethylethoxy)carbonyl>-1-<(phenylmethyl)carbonyl>piperazine-2(S)-carboxamide 
• 911301-77-4 (S)-4-Methanesulfonyl-2-phenylcarbamoyl-piperazine-1-carboxylic acid benzyl ester 
• 911301-76-3 (S)-4-Benzyl-2-phenylcarbamoyl-piperazine-1-carboxylic acid benzyl ester 
• 911301-80-9 (S)-4-Benzenesulfonyl-2-phenylcarbamoyl-piperazine-1-carboxylic acid benzyl ester 
• 911301-81-0 (S)-2-Phenylcarbamoyl-4-(toluene-4-sulfonyl)-piperazine-1-carboxylic acid benzyl ester 
• 911301-82-1 4-(4-tert-butyl-benzenesulfonyl)-2-phenylcarbamoyl-piperazine-1-carboxylic acid benzyl ester 
• 911301-83-2 4-(4-tert-butyl-benzenesulfonyl)-2-(4-methoxy-phenylcarbamoyl)-piperazine-1-carboxylic acid benzyl ester 
• 911301-84-3 4-(4-tert-butyl-benzenesulfonyl)-2-(naphthalen-2-ylcarbamoyl)-piperazine-1-carboxylic acid benzyl ester 
• 903889-85-0 (S)-2-((1S,2S)-2-Acetoxy-1,2-diphenyl-ethylcarbamoyl)-piperazine-1,4-dicarboxylic acid 1-benzyl ester 4-tert-butyl ester 
• 911301-85-4 (S)-2-((1R,2S)-2-Acetoxy-1,2-diphenyl-ethylcarbamoyl)-4-(4-tert-butyl-benzenesulfonyl)-piperazine-1-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

THERAPEUTIC INHIBITORY COMPOUNDS

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds which are complement factor D inhibitors. Such compounds are useful for treating complement related disorders including, but are not limited to, autoimmune, inflammatory, and neurodegenerative diseases.

Heterocyclic core analogs of a direct thrombin inhibitor

Thrombin is a serine protease that plays a key role in blood clotting. Pyrrolidine 1 is a potent thrombin inhibitor discovered at Merck several years ago. Seven analogs (2-8) of 1 in which the pyrrolidine core was replaced with various heterocycles were p

THROMBIN INHIBITORS

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: (I) or a pharmaceutically acceptable salt thereof, wherein Q is CH2, NR4, O, S, S(O) or S(O2

SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smoantagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.

Disubstituted pyrimidines as Lck inhibitors

We have developed a family of 4-benzimidazolyl-N-piperazinethyl-pyrimidin-2-amines that are subnanomolar inhibitors of Lck. A subset of these Lck inhibitors, with heterocyclic substituents at the benzimidazole C5, are also low-nanomolar inhibitors of cell

QUINOLINE DERIVATIVES AS ANTIBACTERIALS

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or N-oxide thereof: corresponding novel medicaments, pharmaceutical compositions and/or methods of

HYDROXAMIC ACID DERIVATIVES

Novel hydroxamic acid derivatives, e.g., of formula (I), wherein R1, R2, R3 and R4 are as defined, are found to be useful as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimm

HIV protease inhibitors useful for the treatment of AIDS

Compounds of formula STR1 where R1 and R2 are independently hydrogen or optionally-substituted C1-4 alkyl or aryl, or R1 and R2 are joined together to form a monocyclic or bicyclic ring system, are HIV protease inhibitors. These compounds are useful in the treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of treating infection by HIV are also described.

L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor

A series of HIV protease inhibitors possessing a hydroxylaminepentanamide transition state isostere have been developed. Incorporation of a basic amine into the backbone of the L-685,434 (2) series provided antiviral potency combined with a highly improved pharmacokinetic profile in animal models. Guided by molecular modeling and an X-ray crystal structure of the inhibited enzyme complex, we were able to design L-735,524. This compound is potent and competitively inhibits HIV-1 PR and HIV-2 PR with K(i) values of 0.52 and 3.3 nM, respectively. It also stops the spread of the HIV-1(IIIb)-infected MT4 lymphoid cells at concentrations of 25-50 nM. To date, numerous HIV-PR inhibitors have been reported, but few have been studied in humans because they lack acceptable oral bioavailability. L-735,524 is orally bioavailable in three animals models, using clinically acceptable formulations, and is currently in phase II human clinical trials.